Skip to main content
Log in

Tricuspid valve replacement and levosimendan

  • Case Report
  • Published:
General Thoracic and Cardiovascular Surgery Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Isolated tricuspid valve replacement, which is not a common operation, is associated with poor shortand long-term results, and the postoperative morbidity and mortality rates are high. The main reason for these adverse effects is the acute manifestation of chronic right heart failure. To treat right heart failure, we used levosimendan for its inotropic and vasodilatatory effects, and it does not increase the calcium overload in myocardial cells. We report two cases of tricuspid valve replacement operations performed using levosimendan. Both patients receiving levosimendan tolerated the operations well, and their postoperative courses were uneventful.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Scully HE, Armstrong CS. Tricuspid valve replacement: fifteen years of experience with mechanical prostheses and bioprostheses. J Thorac Cardiovasc Surg 1995;109:1035–1041.

    Article  PubMed  CAS  Google Scholar 

  2. Jegaden O, Perinetti M, Barthelet M, Vedrinne C, Delahaye F, Montagna P, et al. Long-term results of porcine bioprostheses in the tricuspid position. Eur J Cardiothorac Surg 1992;6:256–260.

    Article  PubMed  CAS  Google Scholar 

  3. Iscan ZH, Vural KM, Bahar I, Mavioglu L, Saritas A. What to expect after tricuspid valve replacement? Long-term results. Eur J Cardiothorac Surg 2007;32:296–300.

    Article  PubMed  Google Scholar 

  4. Mangoni AA, DiSalvo TG, Vlahakes GJ, Polanczyk CA, Fifer MA. Outcome following isolated tricuspid valve replacement. Eur J Cardiothorac Surg 2001;19:68–73.

    Article  PubMed  CAS  Google Scholar 

  5. Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting—a pilot study. Br J Anaesth 2006;96:694–700.

    Article  PubMed  CAS  Google Scholar 

  6. Morais RJ. Levosimendan in severe right ventricular failure following mitral valve replacement. J Cardiothorac Vasc Anesth 2006;20:82–84.

    Article  PubMed  Google Scholar 

  7. Westphal M, Morelli A, Van Aken H. Dear levosimendan, the right ventricle will thank you! Crit Care Med 2007;35:952–953.

    Article  PubMed  Google Scholar 

  8. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006;104:556–569.

    Article  PubMed  CAS  Google Scholar 

  9. Filsoufi F, Anyanwu AC, Salzberg SP, Frankel T, Cohn LH, Adams DH. Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg 2005;80:845–850.

    Article  PubMed  Google Scholar 

  10. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249–259.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Salih Fehmi Katircioglu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cicekcioglu, F., Parlar, A.I., Altinay, L. et al. Tricuspid valve replacement and levosimendan. Gen Thorac Cardiovasc Surg 56, 559–562 (2008). https://doi.org/10.1007/s11748-008-0298-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11748-008-0298-8

Key words

Navigation